Telix To Merge With ITM In Deal Valued At Up To $2.35 Billion
Kort samengevat
Telix Pharmaceuticals (TLX) has agreed to merge with ITM Isotope Technologies Munich SE, a company specializing in radioisotope production and radiopharmaceutical development, in a transaction designed to expand Telix's capabilities across drug development, isotope production, and manufacturing.
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij RTTNews.
Lees het volledige bericht ↗